Pharma BD Deal Intelligence

Pfizer Inc. and Les Laboratoires Servier / Cellectis SA (UCART19 program)

2015 · Licensing/Option · $338M · Complete

Announcement Sentiment

Strongly positive

Servier exercised its exclusive worldwide option from Cellectis for UCART19, an allogeneic CD19 CAR-T, and simultaneously sublicensed US rights to Pfizer. Cellectis received $38.2M at signing plus up to $300M+ in milestones plus royalties. Pfizer's allogeneic CAR-T portfolio later transferred to Allogene Therapeutics (2018); UCART19 program retained by Servier.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Nov 17, 2015
Closed Nov 17, 2015
Deal value $338M
Deal type Licensing/Option
Therapeutic area B-cell acute lymphoblastic leukemia (B-ALL); other CD19+ hematologic malignancies
Indications B-cell acute lymphoblastic leukemia (B-ALL); other CD19+ hematologic malignancies
Key assets UCART19 (allogeneic CAR-T)
Mechanism TALEN gene-edited allogeneic anti-CD19 chimeric antigen receptor T-cell therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals